TFP5/TP5 peptide provides neuroprotection in the MPTP model of Parkinson's disease
Related Experiment Video
Updated: Mar 19, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
B K Binukumar1, Harish C Pant1
1National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Abstract:
Cyclin-dependent kinase 5 (Cdk5) is a member of the serine-threonine kinase family of cyclin-dependent kinases. Cdk5 is critical to normal mammalian nervous system development and plays important regulatory roles in multiple cellular functions. Recent evidence indicates that Cdk5 is inappropriately activated in several neurodegenerative conditions, including Parkinson's disease (PD). PD is a chronic neurodegenerative disorder characterized by the loss of dopamine neurons in the substantia nigra, decreased striatal dopamine levels, and consequent extrapyramidal motor dysfunction. During neurotoxicity, p35 is cleaved to form p25. Binding of p25 with Cdk5 leads deregulation of Cdk5 resulting in number of neurodegenerative pathologies. To date, strategies to specifically inhibit Cdk5 hyperactivity have not been successful without affecting normal Cdk5 activity. Here we show that inhibition of p25/Cdk5 hyperactivation through TFP5/TP5, truncated 24-aa peptide derived from the Cdk5 activator p35 rescues nigrostriatal dopaminergic neurodegeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP/MPP(+)) in a mouse model of PD. TP5 peptide treatment also blocked dopamine depletion in the striatum and improved gait dysfunction after MPTP administration. The neuroprotective effect of TFP5/TP5 peptide is also associated with marked reduction in neuroinflammation and apoptosis. Here we show inhibition of Cdk5/p25-hyperactivation by TFP5/TP5 peptide, which identifies Cdk5/p25 as a potential therapeutic target to reduce neurodegeneration in PD.
Insights
A novel peptide, TFP5/TP5, effectively inhibits the hyperactive Cdk5/p25 complex, offering a potential treatment for Parkinson's disease neurodegeneration.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Cyclin-dependent kinase 5 (Cdk5) is crucial for nervous system development but its aberrant activation contributes to neurodegenerative diseases like Parkinson's disease (PD).
- In PD, the p35 protein is cleaved to p25, leading to Cdk5 deregulation and neurotoxicity.
- Current strategies to inhibit Cdk5 hyperactivity lack specificity, impacting normal cellular functions.
Purpose of the Study:
- To investigate the therapeutic potential of a novel peptide, TFP5/TP5, derived from the Cdk5 activator p35, for treating Parkinson's disease.
- To determine if TFP5/TP5 can inhibit the neurotoxic p25/Cdk5 complex and protect against neurodegeneration.
Main Methods:
- Utilized a mouse model of Parkinson's disease induced by MPTP/MPP+ neurotoxin.
- Administered TFP5/TP5 peptide to assess its effects on nigrostriatal dopaminergic neurodegeneration.
- Evaluated dopamine levels, motor function (gait), neuroinflammation, and apoptosis in treated mice.
Main Results:
- TFP5/TP5 peptide treatment rescued MPTP/MPP+-induced nigrostriatal dopaminergic neurodegeneration.
- The peptide treatment prevented dopamine depletion in the striatum and improved motor deficits.
- TFP5/TP5 administration significantly reduced neuroinflammation and apoptosis, indicating a neuroprotective effect.
Conclusions:
- Inhibition of the hyperactive Cdk5/p25 complex by the TFP5/TP5 peptide demonstrates significant neuroprotective effects in a Parkinson's disease mouse model.
- The Cdk5/p25 complex represents a promising therapeutic target for mitigating neurodegeneration in Parkinson's disease.
- TFP5/TP5 peptide therapy offers a potential strategy for treating Parkinson's disease by targeting a key molecular pathway involved in neurodegeneration.
